DM243 is an EPAC1 activator and STAT3 modulator with an pIC50 of 4.769. DM243 increases GTP-bound Rap1 levels in EPAC1-expressing cells, with no activation of EPAC2 or PKA. DM243 reduces IL-6/IL-6Rα-evoked STAT3 phosphorylation in endothelial cells. DM243 suppresses TGF-β1-induced fibroblast-to-myofibroblast transition, reducing α-smooth muscle actin and Collagen I levels in lung fibroblasts. DM243 exhibits minimal cytotoxicity in normal human lung fibroblasts.

DM175 is a partial agonist of FXR. DM175 binds to the ligand-binding domain of FXR and induces the outward movement of Trp454.

DM-1157 is an orally active asymmetric bisquinoline heme inhibitor with a IC50 of 1.6 μM and a Kd of 1.7 μM. DM-1157 binds to heme dimers in solution, inhibits β-hematin formation, suppresses hemozoin formation in the digestive vacuole of Plasmodium falciparum, accumulates in the digestive vacuole of Plasmodium falciparum, induces enlargement of the digestive vacuole of Plasmodium falciparum, and inhibits the growth of Chloroquine-sensitive and resistant Plasmodium falciparum strains. DM-1157 can be used for the research of malaria and Plasmodium falciparum-type malaria.

DLK-IN-2 is a selective inhibitor of DLK and neuroprotective agent. DLK-IN-2 shows no significant inhibition against CYPs 3A4, 2D6 and 2C9. DLK-IN-2 inhibits acute axonal palmitoylation of DLK, blocks DLK-dependent pro-degenerative axon-to-soma retrograde signaling and suppresses c-Jun phosphorylation. DLK-IN-2 can be used for the mechanistic study of neurodegenerative diseases.

Discodermolide (NVP-XAA-296) is a potent microtubule-stabilizing agent with a Ki of 0.4 μM. Discodermolide stabilizes microtubules, induces G2 or M phase cell cycle arrest and apoptosis, leading to inhibition of cancer cell proliferation. Discodermolide competitively inhibits the binding of Paclitaxel to tubulin polymers, and inhibits the growth of Paclitaxel-resistant cells. Discodermolide can be used for breast and colon cancer research.

Dipotassium [2,2'-biquinoline]-4,4'-dicarboxylate is a metal-organic framework (MOF).

Dioxyindolylalanine, a tryptophan analogue, is an inhibitor of tryptophan synthase.

Dimovarsen, an oligonucleotide, is a micro RNA-132 inhibitsor, and can be use for the study of heart failure.

Dimethyl 3-hydroxyphthalate-amido-C4-N3 is an E3 ligase ligand-linker conjugate containing a CRBN-based ligand and linker, which can be used to synthesize PROTAC.

Dimefluthrin is an insecticide. Dimefluthrin exhibits contact toxicity against large red imported fire ant workers. Dimefluthrin undergoes horizontal transfer among red imported fire ant workers, causing secondary mortality in recipient workers. Dimefluthrin is a neurodevelopmental toxicant, which can reduces acetylcholinesterase activity, impairing neurotransmitter.

DIM-3,5-Cl2 is an inverse NR4A1/NR4A2 agonist with KD values of 7.7 μM and 12.0 μM for NR4A1 and NR4A2, respectively. DIM-3,5-Cl2 acts as an inverse agonist to downregulate pro-oncogenic and proendometriotic gene products, and as an agonist to enhance NR4A1/2/Sp1/Sp4-mediated CD71 transactivation. DIM-3,5-Cl2 induces ferroptosis via ROS formation, lipoperoxidation, MDA production, and reduced GPX4, SLC7A11 expression. DIM-3,5-Cl2 induces apoptosis via PARP and caspase-3 cleavage, reduced BCL-2 expression, and inhibits cancer cell viability. DIM-3,5-Cl2 can be used for the research of triple negative breast cancer, endometriosis, and colorectal cancer.

Dilopetine citrate is an inhibitor of substance P release. Dilopetine citrate dose-dependently reduces the vocalizing of isolated guinea pig pups. Dilopetine citrate shows good activity as an antidepressant.

Dihydro-α-ionone is a volatile compound found in the essential oil of Persicaria hydropiper L. leaves. The essential oil can inhibit α-glucosidase and α-amylase activities.

Dihydrogalanthamine hydrobromide is an acetylcholinesterase inhibitor. Dihydrogalanthamine hydrobromide can be used in research on neurological diseases such as sequelae of poliomyelitis and myasthenia gravis.

Diethyl benzylmalonate is a drug intermediate that can be used for the synthesis of central inhibitory agents.

Diclofop (Dichlorfop acid) is an acetyl-CoA carboxylase (ACC) inhibitor. Diclofop is also the major metabolite of the herbicide Diclofop-methyl. Diclofop exhibits antimalarial activity with an IC50 of 210 μM against P. falciparum.

Dichlorobenzamil (3',4'-Dichlorobenzamil; L-594881) hydrochloride is a Na+-Ca2+ Exchanger inhibitor. Dichlorobenzamil (hydrochloride) attenuates the Na+-Ca2+ exchanger-mediated inward current induced by activation of type I metabotropic glutamate receptors in second-order baroreceptor neurons of the rat nucleus tractus solitarius.

Di(MMY-SJG)-Ph-prop-2-yne-1-sulfonic acid (Compound 5) is a cytotoxic pyrrolobenzodiazepine (PBD) dimer derivative. Di(MMY-SJG)-Ph-prop-2-yne-1-sulfonic acid exhibits moderate DNA alkylating activity. Di(MMY-SJG)-Ph-prop-2-yne-1-sulfonic acid can be used as the payload of ADC, thereby demonstrating strong antigen-dependent cytotoxicity.

DHX9-IN-21 (Compound 635) is a DHX9 inhibitor with an IC50 of 2 nM; its EC50 at the cellular level is 19.1 nM. DHX9-IN-21 exhibits antiproliferative activity against LS411N (CRC-MSI-H), with an IC50 value of 79.2 nM. DHX9-IN-21 can be used for the research of microsatellite unstable colorectal cancer.

DHX9-IN-13 (Example 1) is a RNA helicase DHX9 inhibitor with an EC50 of 16.4 μM. DHX9-IN-13 exhibits biochemical infection point of 0.32 μM. DHX9-IN-13 can be used for the study of cancers.

DHODH-IN-34 (Compound 21q) is a potent human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 value of 13 nM. DHODH-IN-34 is promising for research of RNA viruses such as measles virus and chikungunya virus.

DHFR-IN-25 (Compound N2) is a type of inhibitor of dihydrofolate reductase (DHFR). DHFR-IN-25 is a broad-spectrum and highly effective antibacterial agent, particularly showing significant effects on Candida albicans and Staphylococcus aureus. DHFR-IN-25 can be used for the study of local anti-infection.

DHFR-IN-24, a benzothiazole derivative, is a dihydrofolate reductase (DHFR) inhibitor. DHFR-IN-24 has intrinsic antibacterial activity against both Gram-positive and Gram-negative strains. DHFR-IN-24 synergistically combines DHFR inhibition with photodynamic therapy (PDT) for enhanced antibacterial activity against multidrug-resistant pathogens.

DHAD-IN-2 (compound 6ag) is a potent dihydroxy acid dehydratase (DHAD) inhibitor with a KD of 20 μM. DHAD-IN-2 demonstrates over 85% control effectiveness against Eclipta prostrata, Amaranthus retroflexus, and Setaria viridis at a dosage of 150 g ai/ha, while also showing safety for rice. DHAD-IN-2 can be used for herbicide research.

DGK-IN-13 is a DGK inhibitor. DGK-IN-13 can be used for the research of cancer.

DGK-IN-10 is a DGK inhibitor with IC50 values of ≤ 10 nM for both DGKα and DGKζ. DGK-IN-10 can be used for the research of diseases including cancer.

DFCI-002-06 is an orally active dual-target HCK/BTK PROTAC degrader with DC₅₀ values for HCK and BTK of 1.3 and 4.5 nM respectively. DFCI-002-06 retains higher anti-tumor activity than the HCK/BTK dual-target inhibitor, inducing apoptosis in cancer cells. DFCI-002-06 can be used for the study of MYD88 mutant B-cell malignancies. (Pink: Src and Btk ligand ; Blue: Cereblon ligand ; Black: linker).

Dezaguanine is a purine analog. Dezaguanine exhibits antitumor activity in leukemia and breast cancer cells. Dezaguanine can be used in cancer-related research.

Desmethyl-K777 is a one of the main metabolites of K777.

Desmethylcitalopram hydrobromide (DCIT hydrobromide) is a drug impurity.